Recent News

• 06.04.2025 - Jefferies Global Healthcare Conference
• 05.29.2025 - Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
• 05.19.2025 - Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
• 05.16.2025 - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
• 05.12.2025 - Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
• 05.09.2025 - Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
• 05.07.2025 - Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
• 04.16.2025 - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
• 04.08.2025 - Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
• 04.03.2025 - Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 8-K Current report
• 04.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.28.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.23.2025 - ARS Annual Report to Security Holders
• 04.23.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.23.2025 - DEF 14A Other definitive proxy statements